Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric Medicines
By Amit Chowdhry ● Oct 22, 2024
Seaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a leading global growth investor, led this syndicate, with participation from funds and accounts advised by T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also joined.